MIT researchers published a Nature Nanotechnology paper describing a new degradable cyclic amino ionizable lipid and LNP formulation that delivered an influenza mRNA vaccine at approximately 1/100th the dose of current formulations while maintaining comparable immune responses in mice. The team identified AMG1541 as a top ionizable lipid that improves endosomal escape and biodegradability. The work promises to reduce per‑dose cost and potentially lessen reactogenicity for mRNA vaccines and therapeutics. Translational steps include scalability, manufacturability and toxicology; companies and CDMOs in the mRNA supply chain will watch closely for candidates that accelerate dose‑sparing strategies.